The effects of drugs on the metabolism of glycerolipids is interesting in two respects. First, the drugs may exert part of their pharmacological action by a direct alteration of glycerolipid synthesis or degradation. Secondly, it is possible to use the drugs as biochemical tools to investigate the physiological importance of the enzymes which are affected.
Amphiphilic anionic drugs which are related to p-chlorophenoxyisobutyrate have been widely used as hypolipidaemic agents. They appear to be general inhibitors of the acyltransferase reactions of glycerolipid synthesis Brindley & Bowley, 1975) . This inhibition may arise through a direct inhibition of acyltransferase activity or may be mediated by an altered tissue distribution and metabolism of acyl-CoA esters . The more hydrophobic anions clofenapate and 2-(p-chlorophenyl)-2-(m-trifluoromethylphenoxy)acetate are 20-50 times more potent than p-chlorophenoxyisobutyrate in inhibiting acyltransferase reactions (Brindley & Bowley, 1975) . At concentrations where they inhibited fatty acid esterification, these drugs stimulated the activity of phosphatidate phosphohydrolase (EC 3.1.3.4) up to 2-fold (Brindley & Bowley, 1975) . In rat liver mitochondria clofenapate was more effective in inhibiting dihydroxyacetone phosphate acyltransferase (EC 2.3.1.42) than glycerol phosphate acyltransferase (EC 2.3.1.15) (Bowley et al., 1973) . Clofenapate also selectively inhibited glycerolipid synthesis from glycerol via the esterification of dihydroxyacetone phosphate in rat liver slices. However, in this system clofenapate also acutely inhibited glycerol phosphate oxidoreductase (EC 1 .I .99.5), and this could also have contributed to the decreased esterification of dihydroxyacetone phosphate  Fig. 1 ). This demonstrates the difference between the acute effects of clofenapate and the chronic effects which result in an increased concentration of glycerol phosphate oxidase in mitochondria, probably arising as a compensatory event.
It remains to be proven whether a selective inhibition of the dihydroxyacetone phosphate pathway by amphiphilic anions, such as clofenapate, can account for part of their pharmacological action. If such an effect could be demonstrated in vivo then these drugs might be useful in investigating the physiological functions of thedihydroxyacetone phosphate pathway including the importance of alkyl-and alkenyl-lipid synthesis.
Drugs possessing an amphiphilic cationic structure are poor inhibitors of acyltransferase reactions but they do decrease the activity of phosphatidate phosphohydrolase (Brindley & Bowley, 1975) . This enzyme appears to have important regulatory function in the liver (Mangiapane et al., 1973; Lamb & Fallon, 1974) . It lies at a branch point in metabolism between the synthesis of the acidic lipids such as the phosphoinositides, phosphatidylglycerol and diphosphatidylglycerol, and the more neutral lipids, phosphatidylcholine, phosphatidylethanolamine and triacylglycerol (Fig. 1) 1976) . The drugs which produce these effects include the phenothiazine neuroleptics, tricyclic antidepressants, local anaesthetics, antihistamines, fenfluramine and its derivatives, propranolol and other 8-adrenergic blockers, and some narcotic agents. The mechanism for this redirection of lipid synthesis is illustrated by using chlorpromazine in Fig. 2 . Chlorpromazine and norfenfluramine (Sturton & Brindley, 1977) decrease the flux of phosphatidate to diacylglycerol and increase the synthesis of CDP-diacylglycerol. Since the total flux (in the presence of soluble phosphohydrolase) in these two directions decreases phosphatidate accumulates. The inhibition of phosphatidatephosphohydrolase iscompetitivewithrespect tophosphatidateandresults from the interaction of negatively charged phosphatidate with the positively charged drug.
The increased synthesis of CDP-diacylglycerol in Fig. 2 is not caused by the greater availability of phosphatidate. Further addition of partially purified phosphatidate phosphohydrolase enhanced the flux to diacylglycerol, but does not alter the rate of synthesis of CDP-diacylglycerol (Fig. 2) . Interaction of the drugs with phosphatidate changes its physical properties, including the surface charge, and this increases the activity of the cytidylyltransferase (EC 2.7.7.41) (Sturton & Brindley, 1977) . Progressive addition of Mgz+ also has the effect of increasing the synthesis of CDP-diacylglycerol, while simultaneously decreasing the formation of diacylglycerol. It is possible that part of the physiological control of phosphatidate utilization is brought about by changing the bivalent cation concentration in the vicinity of phosphatidate. The cationic drugs cannot completely replace the requirement for MgZ+ on the cytidylyltransferase reaction, but rather augment its effect (Sturton & Brindley, 1977) . This is an example 4 r
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Fig. 2. Effect of chlorpromazine on the utilization of ['4C]phosphatidate bound to the microsomal membranes of rat liver
Microsomal membranes were pre-labelled with ["Clphosphatidate, and its conversion into diacylglycerol and CDP-diacylglycerol by the endogenous phosphatidate phosphohydrolase and phosphatidate cytidylyltransferase of the membranes was measured (Sturton & Brindley, 1977) . In some incubations the activity of the endogenous phosphatidate phosphohydrolase was supplemented by the addition of a preparation of phosphatidate phosphohydrolase (280pg of protein) that had been partially purified from the soluble fraction of rat liver. The enzyme activities are indicated by: A , total utilization of phospatidate in the presence of the soluble phosphatidate phosphohydrolase (i.e. diacylglycerol plus CDP-diacylglycerol synthesis); A, total utilization of phosphatidate in the absence of soluble phosphohydrolase; o activity of the soluble phosphohydrolase; 0 , activity of the microsomal phosphohydrolase; 0, activity of phosphatidate cytidylyltransferase in the presence of soluble phosphohydrolase; B, activity of the cytidylyltransferase in the absence of soluble phosphohydrolase.
of a co-operative effect between the cationic drugs and bivalent cations as opposed to the antagonistic effects which are often observed. The interaction of amphiphilic cationic drugs with phosphatidate is only one example of a general interaction with acidic phospholipids (Papahadjopoulos et al., 1975) . The drugs change the physical properties of these lipids, their physiological properties in biological membranes and their rates of turnover. The interaction with phosphatidate may be relevant in producing the following phenomena.
(1) The inhibition of phosphatidate phosphohydrolase and a consequent decrease in the rate of triacylglycerol synthesis may be involved in the hypolipidaemic and anti-obesity properties of fenfluramine and its derivatives (Brindley & Bowley, 1975 ; Brindley et al., 1976) .
(2) The redirection of phosphatidate utilization probably partly explains the phospholipidosis which is observed after prolonged treatment with high doses of many cationic drugs. The drugs stimulate the synthesis of acidic lipids which are subsequently transported to the lysosomes with the drugs. The situation is probably aggravated further by an inability of the lysosomes to degrade this abnormal substrate (Michell et al., 1976) .
(3) The cationic drugs which have been discussed generally interfere with membranelinked phenomena, such as movement, fusion, permeability, transport and receptor function (Brindley er al., 1975) . Although these processes are not well understood, the turnover of acidic phospholipids seems to be involved. Cationic drugs have been shown to interfere with this turnover and to control the pattern of phospholipid which is synthesized. This in turn could contribute to the observed changes in membrane properties.
